Mario Enrique Rendón-Macías
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mario Enrique Rendón-Macías has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Juan Manuel Mejía-Aranguré
Laboratorio de Genómica Funcional del Cáncer, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico
3 shared publications Miguel Angel Villasís-Keever
2 shared publications- Alberto Escamilla-Núñez1 shared publication
Armando Kauffman-Nieves
1 shared publication- Arturo Fajardo-Gutiérrez
Unidad de Investigación Médica en Epidemiología Clínica, Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México
1 shared publication - Arturo Fajardo-Gutiérrez
Unidad de Investigación Médica en Epidemiologia Clínica, UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
1 shared publication
Latest Publications
- 23 April 2016
- Vol. 54 (3) , 318-26
[Validation of a clinical nutritional sucking scale].
Suck dysfunction in breastfeeding infants has an impact on their appropriate nutrition. The objective was to build and validate one clinical nutritional sucking scale in the components of sucking, swallowing, and respiration. The scale was carried out in two phases: face-validity and psychometric validity. The first was done by expert consensus. For the second phase, 179 infants (153 healthy newborn and 26 infant less than 6 month of age) and 86 infants with high risk for abnormal sucking were evaluated with the new scale. Three observers evaluated all patients during their feeding. With an initial scale of 10 items we calculated the inter-observer concordance and the internal consistence. With an analysis of the mail components and a discrimination index we reduced to pertinent items. Each component of the scale was compared with clinical variables. We reached a 7 items scale, which showed high reliability (Cronbach's alpha of 0.77 and inter-observer concordance of 0.98. The suck component correlated positively with the ingested volume (Ro = 0.61), the swallow component with the peripheral oxygen saturation (Ro = 0.24), and the breath component with the respiratory frequency (Ro = 0.50). With this scale, we can establish different patterns of sucking abnormalities related with history of neurological abnormalities, hemodynamic alteration and immaturity. In this study the clinical nutritional scale showed to be reliable and valid for its use in sucking problems classification. More studies are required to evaluate its application for oral stimulation therapies.
- 23 April 2016
- Vol. 54 (3) , 318-26
[Validation of a clinical nutritional sucking scale].
Suck dysfunction in breastfeeding infants has an impact on their appropriate nutrition. The objective was to build and validate one clinical nutritional sucking scale in the components of sucking, swallowing, and respiration. The scale was carried out in two phases: face-validity and psychometric validity. The first was done by expert consensus. For the second phase, 179 infants (153 healthy newborn and 26 infant less than 6 month of age) and 86 infants with high risk for abnormal sucking were evaluated with the new scale. Three observers evaluated all patients during their feeding. With an initial scale of 10 items we calculated the inter-observer concordance and the internal consistence. With an analysis of the mail components and a discrimination index we reduced to pertinent items. Each component of the scale was compared with clinical variables. We reached a 7 items scale, which showed high reliability (Cronbach's alpha of 0.77 and inter-observer concordance of 0.98. The suck component correlated positively with the ingested volume (Ro = 0.61), the swallow component with the peripheral oxygen saturation (Ro = 0.24), and the breath component with the respiratory frequency (Ro = 0.50). With this scale, we can establish different patterns of sucking abnormalities related with history of neurological abnormalities, hemodynamic alteration and immaturity. In this study the clinical nutritional scale showed to be reliable and valid for its use in sucking problems classification. More studies are required to evaluate its application for oral stimulation therapies.
- 2 July 2011
- Vol. 63 (2) , 135-47
[The pediatric patient at the end-of-life. A challenge for its identification and treatment. A survey in pediatricians and medical residents].
Identification of pediatric patients at the end-of-life is not easy because criteria used are based on adults' criteria. In this survey we explore the children end-of-life definition pediatricians have, as well as to determine which interventions they use when caring a patient at end-of-life. Tertiary referral pediatric hospital. Staff pediatricians (SP) and medical residents (MR). A self-administrated questionnaire was built and validated. It contains five vignettes of pediatric patients: Two with WHO criteria for an end-of-life condition (EC) and three without an end-of-life condition (NEC). PARTICIPANTS identified each patient with or without an end-of-life condition, and which palliative actions they would perform accordingly Their responses were recorded in a 4-option Likert scale. Ordinal regression was used to assess if some of the participants' characteristics were related to the identification of an end-of-life condition. Response rate was 84.2% (128/152); of whom 63 were SP and 65 MR. EC cases were well identified in 90 and 93%, while NEC in 30 and 40%, respectively Palliative actions were more according in EC patients, but around 20% would not provide them. Among NEC patients, there were more disparities of palliative actions to be delivered, and it was statistically significantly. Ordinal regression showed that some participants' characteristics are associated to the appropriate identification of end-of-life patients; however, these factors were not consistent across the five scenarios. Among pediatricians, criteria of end-of-life conditions are not well established, neither the palliative actions. Educational interventions are needed to improve the quality of life of these children.
- 2 July 2011
- Vol. 63 (2) , 135-47
[The pediatric patient at the end-of-life. A challenge for its identification and treatment. A survey in pediatricians and medical residents].
Identification of pediatric patients at the end-of-life is not easy because criteria used are based on adults' criteria. In this survey we explore the children end-of-life definition pediatricians have, as well as to determine which interventions they use when caring a patient at end-of-life. Tertiary referral pediatric hospital. Staff pediatricians (SP) and medical residents (MR). A self-administrated questionnaire was built and validated. It contains five vignettes of pediatric patients: Two with WHO criteria for an end-of-life condition (EC) and three without an end-of-life condition (NEC). PARTICIPANTS identified each patient with or without an end-of-life condition, and which palliative actions they would perform accordingly Their responses were recorded in a 4-option Likert scale. Ordinal regression was used to assess if some of the participants' characteristics were related to the identification of an end-of-life condition. Response rate was 84.2% (128/152); of whom 63 were SP and 65 MR. EC cases were well identified in 90 and 93%, while NEC in 30 and 40%, respectively Palliative actions were more according in EC patients, but around 20% would not provide them. Among NEC patients, there were more disparities of palliative actions to be delivered, and it was statistically significantly. Ordinal regression showed that some participants' characteristics are associated to the appropriate identification of end-of-life patients; however, these factors were not consistent across the five scenarios. Among pediatricians, criteria of end-of-life conditions are not well established, neither the palliative actions. Educational interventions are needed to improve the quality of life of these children.
- 1 January 2011
- p. S43-70
[Cancer epidemiology in Mexican children. Overall results].
A total of 3238 new cases of childhood cancer were registered during the period under study (1996-2007). These cases showed predominately the Northamerican/European pattern of neoplasias: leukemias were the most frequent (46.1%), followed by tumors of the central nervous system (CNST, 12.0%), and lymphomas (10.8%); the overall incidence was 125.6 (all rates per 1000 000 children/year), with incidences of 136.3, 164.1, 95.2, 114.7, for < 1, 1-4, 5-9, 10-14 age group, respectively. Compared to children in the United States, Mexican children had a greater incidence of leukemias, retinoblastomas, and germ cell tumors; a lower incidence of CNST, neuroblastomas, kidney tumors, soft-tissue sarcomas, and carcinomas; and similar incidences of lymphomas, liver tumors, and bone tumors. The male/female ratio was 1.1 and the highest incidence was found for those less than five years of age. Overall, the incidence showed a trends to decrease (average annual percent change (AAPC), -3.3; CI 95%, -6.3, -0.1), with the greatest decrease during the period 1996-2000 (AAPC, -7.9; CI 95%, -15.5, 0.3) and remaining stable thereafter (2000-2007) (AAPC, -0.5; CI 95%, -4.0, 3.2). Stages III and IV were found in 57.4 % of the cases of solid tumors.
- 1 January 2011
- p. S43-70
[Cancer epidemiology in Mexican children. Overall results].
A total of 3238 new cases of childhood cancer were registered during the period under study (1996-2007). These cases showed predominately the Northamerican/European pattern of neoplasias: leukemias were the most frequent (46.1%), followed by tumors of the central nervous system (CNST, 12.0%), and lymphomas (10.8%); the overall incidence was 125.6 (all rates per 1000 000 children/year), with incidences of 136.3, 164.1, 95.2, 114.7, for < 1, 1-4, 5-9, 10-14 age group, respectively. Compared to children in the United States, Mexican children had a greater incidence of leukemias, retinoblastomas, and germ cell tumors; a lower incidence of CNST, neuroblastomas, kidney tumors, soft-tissue sarcomas, and carcinomas; and similar incidences of lymphomas, liver tumors, and bone tumors. The male/female ratio was 1.1 and the highest incidence was found for those less than five years of age. Overall, the incidence showed a trends to decrease (average annual percent change (AAPC), -3.3; CI 95%, -6.3, -0.1), with the greatest decrease during the period 1996-2000 (AAPC, -7.9; CI 95%, -15.5, 0.3) and remaining stable thereafter (2000-2007) (AAPC, -0.5; CI 95%, -4.0, 3.2). Stages III and IV were found in 57.4 % of the cases of solid tumors.
- 10 April 2010
- Vol. 23 (6) , 342-50
[Systematic review to assess the effectiveness and safety of parecoxib].
Conduct a meta-analysis of randomized clinical trials to assess the effectiveness and safety of parecoxib as analgesic for orthopedic surgery. The search strategy included Medline, Embase and Cochrane. Two independent investigators selected the trials. The meta-analyses were performed using the RevMan v.5.0 software. Calculations were based on the similarity of the trials considering the parecoxib dose (20 or 40 mg) and the type of comparator (placebo, other analgesics). A total of 1253 titles were reviewed and 10 trials that assess parecoxib for hip, knee and spine surgery and bunionectomy were selected. In 6/10 trials parecoxib 40 mg did better in the overall assessment versus the placebo (OR 0.20; 95% CI, 0.13-0.31), in the frequency of rescue analgesic use (OR 0.18; 95% CI, 0.07-0.47) as well as in the use of morphine and in pain intensity at 48 hours (p < 0.001). Three trials did not show any difference between parecoxib and ketorolac, morphine, metamizole or paracetamol. Regarding safety, the frequency of adverse events with parecoxib was similar to the placebo or other analgesics. Parecoxib 40 mg is an effective and safe analgesic choice during the postoperative period in orthopedic surgery.
- 10 April 2010
- Vol. 23 (6) , 342-50
[Systematic review to assess the effectiveness and safety of parecoxib].
Conduct a meta-analysis of randomized clinical trials to assess the effectiveness and safety of parecoxib as analgesic for orthopedic surgery. The search strategy included Medline, Embase and Cochrane. Two independent investigators selected the trials. The meta-analyses were performed using the RevMan v.5.0 software. Calculations were based on the similarity of the trials considering the parecoxib dose (20 or 40 mg) and the type of comparator (placebo, other analgesics). A total of 1253 titles were reviewed and 10 trials that assess parecoxib for hip, knee and spine surgery and bunionectomy were selected. In 6/10 trials parecoxib 40 mg did better in the overall assessment versus the placebo (OR 0.20; 95% CI, 0.13-0.31), in the frequency of rescue analgesic use (OR 0.18; 95% CI, 0.07-0.47) as well as in the use of morphine and in pain intensity at 48 hours (p < 0.001). Three trials did not show any difference between parecoxib and ketorolac, morphine, metamizole or paracetamol. Regarding safety, the frequency of adverse events with parecoxib was similar to the placebo or other analgesics. Parecoxib 40 mg is an effective and safe analgesic choice during the postoperative period in orthopedic surgery.
- 25 October 2003
- Vol. 139 (4) , 325-36
[Trends of 6 primary causes of mortality in Mexican children in 1971-2000. Epidemiologic transition in children].
To determine trends of six main causes of mortality in Mexican children < 15 years of age. Observational, descriptive and retrospective. January 1, 1971 to December 31, 2000. Studied Population: Children < 15 years of age, Statistic Analysis: mortality rates were obtained due to perinatal causes, respiratory infections, intestinal infections, accidents, congenital malformations (CM), and cancer (CA). They were stratified according to age groups in < 1 year, 1 to 4 years, 5 to 14 years, and 1 to 14 years of age. Percentage differences were calculated between 1971 and 2000, as were respective trends. Global decrease in mortality was according to age group, 83.5% in 0 to 14-year-old, 71.3% in under one year old, 90.5 in 1 to 4-years-old, 79.2% in 5 to 14-year-old. The largest decrease in all groups was observed for infectious causes (> 90%), and increased CM between 120.1 to 160.5%, and CA between 28.0 to 56.4%. Mortality in Mexican children has decreased significantly. Infectious causes show the most important reduction, the CM and CA showing largest increase. Accidents, although they reveal some tendency to decrease, are first cause of death in the group 1 to 14 years of age. Present data indicate the need to continue programs to provide care for infections diseases, and to establish new programs that include care for accidents, CM, and CA in children.
- 25 October 2003
- Vol. 139 (4) , 325-36
[Trends of 6 primary causes of mortality in Mexican children in 1971-2000. Epidemiologic transition in children].
To determine trends of six main causes of mortality in Mexican children < 15 years of age. Observational, descriptive and retrospective. January 1, 1971 to December 31, 2000. Studied Population: Children < 15 years of age, Statistic Analysis: mortality rates were obtained due to perinatal causes, respiratory infections, intestinal infections, accidents, congenital malformations (CM), and cancer (CA). They were stratified according to age groups in < 1 year, 1 to 4 years, 5 to 14 years, and 1 to 14 years of age. Percentage differences were calculated between 1971 and 2000, as were respective trends. Global decrease in mortality was according to age group, 83.5% in 0 to 14-year-old, 71.3% in under one year old, 90.5 in 1 to 4-years-old, 79.2% in 5 to 14-year-old. The largest decrease in all groups was observed for infectious causes (> 90%), and increased CM between 120.1 to 160.5%, and CA between 28.0 to 56.4%. Mortality in Mexican children has decreased significantly. Infectious causes show the most important reduction, the CM and CA showing largest increase. Accidents, although they reveal some tendency to decrease, are first cause of death in the group 1 to 14 years of age. Present data indicate the need to continue programs to provide care for infections diseases, and to establish new programs that include care for accidents, CM, and CA in children.
- 1 May 2002
- Published by Elsevier in Archives of Medical Research
- Vol. 33 (3) , 269-275
Breastfeeding Among Patients with Congenital Malformations
- 1 May 2002
- Published by Elsevier in Archives of Medical Research
- Vol. 33 (3) , 269-275
Breastfeeding Among Patients with Congenital Malformations